Literature DB >> 7642290

Mechanisms of inhibition of Cryptococcus neoformans by human lymphocytes.

S M Levitz1, E A North, M P Dupont, T S Harrison.   

Abstract

Recently, our laboratory and others have demonstrated that human peripheral blood T and NK lymphocytes directly inhibit the growth of Cryptococcus neoformans. In this study, we further define the conditions under which lymphocyte-mediated fungistasis against C. neoformans occurs and examine whether mechanisms implicated in lymphocyte-mediated activities against other target cells are also involved in anticryptococcal activity. The addition of whole or broken heat-killed C. neoformans modestly inhibited lymphocyte-mediated fungistasis, whereas other particulates had no effect. The hydroxyl radical scavenger catechin, but not diethyl urea or propyl gallate, profoundly inhibited fungistasis. Salicylic acid inhibited fungistasis in a dose-dependent fashion. However, two other cyclooxygenase inhibitors, piroxicam and indomethacin, had no effect, suggesting that the mechanism of inhibition by salicylic acid was cyclooxygenase independent. Reagent prostaglandin E2, at concentrations shown by others to inhibit NK cell-mediated bactericidal and tumorlytic activities, had no effect on lymphocyte-mediated fungistasis. The addition of selected monoclonal antibodies or ligands reactive with receptors on human lymphocytes had no significant effect on lymphocyte-mediated fungistasis. Acapsular, small-capsuled, and large-capsuled C. neoformans organisms were inhibited by lymphocytes to an approximately equal extent. These data demonstrate that lymphocyte-mediated activity against C. neoformans proceeds regardless of the presence of capsule and by mechanisms at least in part dissimilar from those seen with other target cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642290      PMCID: PMC173492          DOI: 10.1128/iai.63.9.3550-3554.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.

Authors:  D Kägi; B Ledermann; K Bürki; P Seiler; B Odermatt; K J Olsen; E R Podack; R M Zinkernagel; H Hengartner
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

2.  Restoration of lytic function in a human natural killer cell line by gene transfection.

Authors:  J H Liu; S Wei; D K Blanchard; J Y Djeu
Journal:  Cell Immunol       Date:  1994-06       Impact factor: 4.868

Review 3.  The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects.

Authors:  G Berke
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

4.  Target cell-induced inactivation of cytolytic lymphocytes. Role and regulation of CD45 and calyculin A-inhibited phosphatase in response to interleukin-2.

Authors:  A Bajpai; Z Brahmi
Journal:  J Biol Chem       Date:  1994-07-22       Impact factor: 5.157

5.  Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans.

Authors:  S M Levitz; A Tabuni; H Kornfeld; C C Reardon; D T Golenbock
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells.

Authors:  P A Mathew; B A Garni-Wagner; K Land; A Takashima; E Stoneman; M Bennett; V Kumar
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

Review 7.  The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis.

Authors:  S M Levitz
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

8.  Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans.

Authors:  S M Levitz; M P Dupont; E H Smail
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

9.  Expression of the NK-TR gene is required for NK-like activity in human T cells.

Authors:  C A Chambers; S Gallinger; S K Anderson; S Giardina; J R Ortaldo; N Hozumi; J Roder
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

10.  Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.

Authors:  D C Houpt; G S Pfrommer; B J Young; T A Larson; T R Kozel
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

View more
  7 in total

Review 1.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Host defence to pulmonary mycosis.

Authors:  C H Mody; P W Warren
Journal:  Can J Infect Dis       Date:  1999-03

3.  Host response to pulmonary fungal infections: A highlight on cell-driven immunity to Cryptococcus species and Aspergillus fumigatus.

Authors:  Orchi Dutta; Jorge A Masso-Silva; Keyi Wang; Amariliz Rivera
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

4.  T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.

Authors:  R R Yuan; A Casadevall; J Oh; M D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

Review 5.  Direct microbicidal activity of cytotoxic T-lymphocytes.

Authors:  Paul Oykhman; Christopher H Mody
Journal:  J Biomed Biotechnol       Date:  2010-06-23

6.  gamma Interferon gene expression and release in human lymphocytes directly activated by Cryptococcus neoformans and Candida albicans.

Authors:  S M Levitz; E A North
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

7.  Cryptococcus neoformans directly stimulates perforin production and rearms NK cells for enhanced anticryptococcal microbicidal activity.

Authors:  Kaleb J Marr; Gareth J Jones; Chunfu Zheng; Shaunna M Huston; Martina Timm-McCann; Anowara Islam; Byron M Berenger; Ling Ling Ma; Jeremy C D Wiseman; Christopher H Mody
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.